VivoSeq
Gastroenterology

Fatty Liver Disease

19

Pipeline Programs↗

7

Active Trials↗

16

Companies Involved↗

Fatty Liver Disease is an emerging landscape with 19 programs across 16 companies. The most active players are Otsuka, Boehringer Ingelheim, Validus Pharmaceuticals. 6 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

15/100

Mech. Concentration

15/100

Completion Rate

75/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Otsuka logo

Otsuka

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 1V

Validus Pharmaceuticals

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2G

Galmed Pharmaceuticals Ltd

1 program

Phase 2Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

19 of 23 classified programs — the dominant modality here.

17%ALL OTHERSPeptide313%Vaccine14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed9 · 39%
Recruiting4 · 17%
Unknown status4 · 17%
Not yet recruiting3 · 13%
Terminated2 · 9%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

23 trials

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Recruiting·SSeoul National University Bundang Hospital·Phase 4·NCT06989723·120 enrolled
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Recruiting·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06884293·470 enrolled
NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease
Recruiting·UUniversity of California, Davis·Phase 1·NCT06453915·12 enrolled
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Recruiting·HHudson Biotech·Phase 2·NCT07481734·120 enrolled
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
Not yet recruiting·IInsel Gruppe AG, University Hospital Bern·N/A·NCT06546384·64 enrolled
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Not yet recruiting·IInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval·N/A·NCT06764056·120 enrolled
Efficacy and Safety of a High-Protein Diet Versus a Standard Diet in Patients With Alcoholic Fatty Liver Disease: A Randomized Controlled Trial
Not yet recruiting·LLi Lab,MD·Preclinical·NCT07632222·74 enrolled
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
Completed·Novo Nordisk logoNovo Nordisk·Phase 2·NCT03987451·71 enrolled
Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease
Completed·GGW Research Ltd·Phase 2·NCT01284634·25 enrolled
Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis
Completed·GGalmed Medical Reserch·Phase 2·NCT01094158·60 enrolled
A Phase 2b Study of Icosabutate in Fatty Liver Disease
Completed·NNorthSea Therapeutics B.V.·Phase 2·NCT04052516·280 enrolled
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment
Completed·—·N/A·NCT05694923·55 enrolled
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT05970640·64 enrolled
The Effect of Pentoxifylline on Liver Function Tests in Fatty Liver Disease
Completed·TTehran University of Medical Sciences·Phase 2·NCT02283710·120 enrolled
Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution
Completed·—·Phase 1·NCT04853082·57 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)